Nearly One Third of the Total HIFU Manufacturers are based in European region

ATLANTA - May 22, 2017 - PRLog -- Free 10% Customization in this Report

High-Intensity Focused Ultrasound (HIFU) is an FDA-approved, minimally invasive therapeutic technology with the potential to transform the treatment of many medical disorders by using ultrasonic energy to target tissue. Till date more than 100,000 patients have been treated with HIFU therapeutic technology; nearly 25,000 patients alone treated in 2015. New regulatory approvals in United States and other part of the world, expansion of research and treatment sites and innovation continues in new companies are some the growth driving factors for HIFU devices.

Prostate Cancer is the Leading use of HIFU Technology Globally

Prostate cancer is one of the common types of cancer in the men. Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. It is estimated that nearly 161,360 new cases of prostate cancer will be found in the United States and nearly 26,730 men is expected to die in 2017.

About One Third of the Total HIFU Patients are Treated for Uterine Fibroids Cases in 2015

Uterine fibroids are benign tumors that originate in the uterus. Most of the women did not found any symptoms whereas some women have painful period. The exact cause of uterine fibroids is unclear. Uterine fibroids are the other leading application for HIFU device. About one third of the total HIFU patients are treated for uterine fibroids cases in 2015.

Download full Report:  http://www.renub.com/high-intensity-focused-ultrasound-hifu-product-analysis-of-20-manufacturers-and-deals-1093-p.php